Alzheimer's disease: exploring the pathogenesis, progression, and strategies for management | ||||
| Aswan Science and Technology Bulletin | ||||
| Volume 3, Issue 1, June 2025, Page 132-158 PDF (569.23 K) | ||||
| Document Type: Review article | ||||
| DOI: 10.21608/astb.2025.354245.1016 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
safinaz A elbaga 1; Eatemad Awadalla  2; Mohammed Hosny Hassaan3; Abdelkader Mohamed Abdelkader2
| ||||
| 1Zoology department, Faculty of Science, Aswan University, Aswan, Egypt | ||||
| 2Aswan University | ||||
| 3Medical Biochemistry Dep., Faculty Of Medicine, South Valley University, Qena, Egypt | ||||
| Abstract | ||||
| Alzheimer’s disease (AD), a devastating neurodegenerative disease with many possible etiologies that have been explained and associated with spatial disorientation, memory loss and the gradual decline of intellectual capacity. The current research on neurodegenerative illnesses has put certain candidate compounds through clinical trials. Many reasons have been linked with the increase of AD risk. The progression of AD is marked by gradual cognitive decline, brain alterations such as decreased information transfer throughout synapses, which results in the death of neurons, thus contributive to the decline of functional and cognitive abilities Early diagnosis, coupled with a better understanding of biomarkers, is crucial for improving patient outcomes and developing targeted therapies. Even though it was first recognized over a century ago, AD is still an incurable disease. Only four medications have been accepted by the European Medicines Agency and the Food and Drug Administration for the treatment of cognitive symptoms; these medications, however, cannot stop or slow the disease's progression, neurodegeneration, or memory loss. | ||||
| Keywords | ||||
| Alzheimer`s disease; cognitive decline; risk factors; progression and therapeutic targets | ||||
|
Statistics Article View: 64 PDF Download: 60 |
||||
